Synonyms: SNDX-5613 | SNDX5613
Compound class:
Synthetic organic
Comment: The chemical structure for revumenib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as an antineoplastic agent. It resolved to Syndax Pharmaceuticals' SNDX-5613 via a PubChem match on SMILES. SNDX-5613 inhbits the Menin-MLL protein-protein interaction, as a strategy that's being investigated to treat MLL-rearranged leukemias (such as ALL and AML) [1]. Menin inhibitors promote differentiation and apoptosis of MLL-rearranged AML cells in vitro.
|
|
Classification | |
Compound class | Synthetic organic |
International Nonproprietary Names | |
INN number | INN |
11657 | revumenib |
Synonyms |
SNDX-5613 | SNDX5613 |
Database Links | |
CAS Registry No. | 2169919-21-3 (source: WHO INN list) |
ChEMBL Ligand | CHEMBL4650827 |
GtoPdb PubChem SID | 461663438 |
PubChem CID | 132212657 |
RCSB PDB Ligand | OQ4 |
Search Google for chemical match using the InChIKey | FRVSRBKUQZKTOW-YOCNBXQISA-N |
Search Google for chemicals with the same backbone | FRVSRBKUQZKTOW |
Search PubMed clinical trials | revumenib |
Search PubMed titles | revumenib |
Search PubMed titles/abstracts | revumenib |
UniChem Compound Search for chemical match using the InChIKey | FRVSRBKUQZKTOW-YOCNBXQISA-N |
UniChem Connectivity Search for chemical match using the InChIKey | FRVSRBKUQZKTOW-YOCNBXQISA-N |